Innovating Works

Lysogene

Desconocido
SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol... LYSOGENE participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado
ARDAT: Accelerating Research Development for Advanced Therapies LYSOGENE participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado
ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach... LYSOGENE participó en un H2020: H2020-JTI-IMI2-2015-04-two-stage-Master Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.